Page 4 - Front Immunol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

2Informatic Unit, INMEDIT SAS and Faculty of Engineering, University of Cartagena, Cartagena, Colombia 3Clinica Respiratoria y de Alergias, Cartagena, Colombia 4Departamento de Investigaciones, Fundación Cardioinfantil, Bogotá, Colombia 5Research Department - CINEUMO, Fundación Neumológica Colombiana, Bogotá, Colombia 6Research Department and Specialization Program in Pulmonology, Universidad de la Sabana, Bogotá, Colombia Background: Chronic obstructive pulmonary disease (COPD) is associated with increased risk of severe COVID-19, but the mechanisms are unclear. Besides, patients with ...

2Luebeck Institute of Experimental Dermatology, University of Luebeck, Luebeck, Germany 3General Surgery Department, Tawam Hospital, SEHA, Al Ain, United Arab Emirates 4Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates 5Department of Genetics and Molecular Biology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates 6Department of Respiratory Medicine, Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates 7Meakins-Christie Laboratories, McGill University, Montreal, QC, Canada 8Division of Surgery an...

1* 1Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, United States 2Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, United States 3Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, United States 4Department of Pathology, Division of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, AL, United States Tumor-stromal interactions within the tumor microenvironment (TME) influence lung cancer progression and...

Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma Amgen and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroid dose, without loss of asthma control, with tezepelumab compared to placebo. The 48-week trial assessed the efficacy and safety of the potential new medicine tezepelumab compared to placebo in 150 severe asthma patients who required maintenance use of oral … Amgen (NASDAQ:AMGN) and AstraZeneca today announced the SOURCE tria...